199 related articles for article (PubMed ID: 32665104)
21. 2015/2016 Quality Risk Management Benchmarking Survey.
Waldron K; Ramnarine E; Hartman J
PDA J Pharm Sci Technol; 2017; 71(5):330-345. PubMed ID: 28512175
[TBL] [Abstract][Full Text] [Related]
22. A Risk Index and Data Display for Process Performance in the Pharmaceutical Industry.
Gunter B; Coleman D; Goerke A; Koulis T; Lamerz J; Peng Y
PDA J Pharm Sci Technol; 2018; 72(2):188-198. PubMed ID: 29242393
[TBL] [Abstract][Full Text] [Related]
23. A new roadmap for biopharmaceutical drug product development: Integrating development, validation, and quality by design.
Martin-Moe S; Lim FJ; Wong RL; Sreedhara A; Sundaram J; Sane SU
J Pharm Sci; 2011 Aug; 100(8):3031-3043. PubMed ID: 21425164
[TBL] [Abstract][Full Text] [Related]
24. System-wide hybrid MPC-PID control of a continuous pharmaceutical tablet manufacturing process via direct compaction.
Singh R; Ierapetritou M; Ramachandran R
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1164-82. PubMed ID: 23523542
[TBL] [Abstract][Full Text] [Related]
25. Quality by design for herbal drugs: a feedforward control strategy and an approach to define the acceptable ranges of critical quality attributes.
Yan B; Li Y; Guo Z; Qu H
Phytochem Anal; 2014; 25(1):59-65. PubMed ID: 24108478
[TBL] [Abstract][Full Text] [Related]
26. Biopharmaceutical Industry Practices for Sequence Variant Analyses of Recombinant Protein Therapeutics.
Valliere-Douglass J; Marzilli L; Deora A; Du Z; He L; Kumar SR; Liu YH; Mueller HM; Nwosu C; Stults J; Wang Y; Yaghmour S; Zhou Y
PDA J Pharm Sci Technol; 2019; 73(6):622-634. PubMed ID: 31209169
[TBL] [Abstract][Full Text] [Related]
27. Quality by design approach for formulation development: a case study of dispersible tablets.
Charoo NA; Shamsher AA; Zidan AS; Rahman Z
Int J Pharm; 2012 Feb; 423(2):167-78. PubMed ID: 22209997
[TBL] [Abstract][Full Text] [Related]
28. Opportunities and challenges of real-time release testing in biopharmaceutical manufacturing.
Jiang M; Severson KA; Love JC; Madden H; Swann P; Zang L; Braatz RD
Biotechnol Bioeng; 2017 Nov; 114(11):2445-2456. PubMed ID: 28710854
[TBL] [Abstract][Full Text] [Related]
29. Quality by design (QbD) approaches in current pharmaceutical set-up.
Mishra V; Thakur S; Patil A; Shukla A
Expert Opin Drug Deliv; 2018 Aug; 15(8):737-758. PubMed ID: 30044646
[TBL] [Abstract][Full Text] [Related]
30. Role of Knowledge Management in Development and Lifecycle Management of Biopharmaceuticals.
Rathore AS; Garcia-Aponte OF; Golabgir A; Vallejo-Diaz BM; Herwig C
Pharm Res; 2017 Feb; 34(2):243-256. PubMed ID: 27785590
[TBL] [Abstract][Full Text] [Related]
31. Acceptance Probability (P a) Analysis for Process Validation Lifecycle Stages.
Alsmeyer D; Pazhayattil A; Chen S; Munaretto F; Hye M; Sanghvi P
AAPS PharmSciTech; 2016 Apr; 17(2):516-22. PubMed ID: 26024723
[TBL] [Abstract][Full Text] [Related]
32. Improving drug manufacturing with process analytical technology.
Rodrigues LO; Alves TP; Cardoso JP; Menezes JC
IDrugs; 2006 Jan; 9(1):44-8. PubMed ID: 16374733
[TBL] [Abstract][Full Text] [Related]
33. Analytical Method Lifecycle Management in Pharmaceutical Industry: a Review.
Volta E Sousa L; Gonçalves R; Menezes JC; Ramos A
AAPS PharmSciTech; 2021 Apr; 22(3):128. PubMed ID: 33835304
[TBL] [Abstract][Full Text] [Related]
34. Quality-by-Design II: Application of Quantitative Risk Analysis to the Formulation of Ciprofloxacin Tablets.
Claycamp HG; Kona R; Fahmy R; Hoag SW
AAPS PharmSciTech; 2016 Apr; 17(2):233-44. PubMed ID: 26202064
[TBL] [Abstract][Full Text] [Related]
35. Technical Decision Making With Higher Order Structure Data: Perspectives on Higher Order Structure Characterization From the Biopharmaceutical Industry.
Weiss WF; Gabrielson JP; Al-Azzam W; Chen G; Davis DL; Das TK; Hayes DB; Houde D; Singh SK
J Pharm Sci; 2016 Dec; 105(12):3465-3470. PubMed ID: 27743675
[TBL] [Abstract][Full Text] [Related]
36. White paper on continuous bioprocessing. May 20-21, 2014 Continuous Manufacturing Symposium.
Konstantinov KB; Cooney CL
J Pharm Sci; 2015 Mar; 104(3):813-20. PubMed ID: 25417595
[TBL] [Abstract][Full Text] [Related]
37. An Industry Perspective on the use of Forced Degradation Studies to Assess Comparability of Biopharmaceuticals.
Campbell JM; Colombo S; Doyle JL; Filoti DI; Hübner G; Magnenat L; Nowinski AK; Pavon JA; Singh SM; Vo LR; Woods JM; Stokes ESE
J Pharm Sci; 2024 Mar; 113(3):505-512. PubMed ID: 38103689
[TBL] [Abstract][Full Text] [Related]
38. Mixing monoclonal antibody formulations using bottom-mounted mixers: impact of mechanism and design on drug product quality.
Gikanga B; Chen Y; Stauch OB; Maa YF
PDA J Pharm Sci Technol; 2015; 69(2):284-96. PubMed ID: 25868994
[TBL] [Abstract][Full Text] [Related]
39. Scientific and Regulatory Considerations in Solid Oral Modified Release Drug Product Development.
Li M; Sander S; Duan J; Rosencrance S; Miksinski SP; Yu L; Seo P; Rege B
AAPS J; 2016 Nov; 18(6):1406-1417. PubMed ID: 27650190
[TBL] [Abstract][Full Text] [Related]
40. Benchmarking safety pharmacology regulatory packages and best practice.
Lindgren S; Bass AS; Briscoe R; Bruse K; Friedrichs GS; Kallman MJ; Markgraf C; Patmore L; Pugsley MK
J Pharmacol Toxicol Methods; 2008; 58(2):99-109. PubMed ID: 18692579
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
